Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LaserSight Views Pricing Options As Key To LaserScan Marketing Plan

This article was originally published in The Gray Sheet

Executive Summary

LaserSight is highlighting its flexible payment and pricing scheme for its firm's LaserScan LSX ophthalmic excimer laser system as the firm gears up to compete with market leader Visx, with which it withdrew from patent licensing negotiations on Feb. 1.

You may also be interested in...



Summit's Integrated Wavefront Technology To Break In 2001

Summit Technology, backed by encouraging results from 20 patients treated thus far in an ongoing feasibility trial, is hoping to market a customized refractive laser surgical system integrating the company's CustomCornea wavefront measuring device with its LADARVision system by the end of 2001.

Visx v. Nidek ITC LASIK Ruling May Open Door For Bausch & Lomb, Others

A recent ruling by the International Trade Commission weakens, at least temporarily, the patent position of Visx and co-licensor Summit Technology in the rapidly growing laser-assisted in situ keratomileusis (LASIK) market, and creates an opening for a formidable competitor, Bausch & Lomb, whose Technolas LASIK device awaits FDA approval.

Cosmetic And Personal Care Trademark Review: 9 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012930

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel